Premium
The efficacy and toxicity of VAD in the treatment of myeloma and related disorders
Author(s) -
Sheehan T.,
Judge M.,
Parker A. C.
Publication year - 1986
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1986.tb02632.x
Subject(s) - multiple myeloma , medicine , toxicity , refractory (planetary science) , vincristine , complication , first line , oncology , chemotherapy , cyclophosphamide , biology , astrobiology
Impressive results have recently been reported in 29 cases of advanced refractory myeloma treated with 4‐d infusions of Vincristine and Adriamycin (VAD). We report our own experience with this protocol in 13 cases of myeloma and related lympho‐proliferative disorders. In 2 of these cases, VAD was used as first line treatment. Objective responses were seen in two‐thirds of cases and the major complication of therapy was infection, predominantly bacterial in nature.